Almirall Rises After Lung Disease Drug Clears FDA: Madrid Mover

Almirall SA rose the most in five months in Madrid trading after it won U.S. approval for a drug developed with Forest Laboratories Inc. to help people with a chronic lung disease breathe more easily.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.